Warren Buffett Adds More DaVita HealthCare Partners Inc (DVA) to Berkshire’s Portfolio

According to a filing with the SEC, Warren Buffett’s holding company Berkshire Hathaway has continued to buy shares of DaVita HealthCare Partners Inc (NYSE:DVA), a $12 billion market cap provider of kidney dialysis services at hospitals and dialysis centers. Adding over 600,000 shares of the stock in early July, Berkshire reported close to 16 million shares of the stock as of July 3rd. As a result Buffett’s stake in the company is worth about $1.8 billion at current prices. We track quarterly 13F filings from hundreds of hedge funds and other notable investors such as Berkshire as part of our work researching investment strategies (we have found, for example, that the most popular small cap stocks among hedge funds earn an average excess return of 18 percentage points per year); according to our database, Buffett’s company owned about 15 million shares as of the end of March (find Buffett’s favorite stocks).

In the first quarter of 2013, DaVita HealthCare Partners Inc’s net patient service revenues increased by 12% versus a year earlier, with overall revenue growing to a greater degree due to the company’s merger with Health Care Partners, now a subsidiary of the business. DaVita HealthCare Partners Inc wrote a $300 million loss contingency reserve during the quarter, which caused its pretax income to be much lower than its levels a year ago; if we add back that reserve, however, we get a 39% increase in income before taxes.

Because of the recent acquisition and the contingency reserve, trailing EPS numbers aren’t that relevant to DaVita HealthCare Partners Inc’s valuation and we can’t really use the Q1 numbers as a guide to future performance either. Wall Street analysts are predicting that earnings per share for this year will come in at $7.51- making for a current-year P/E multiple of 15- and then experience only weak growth in the next year. That’s a decent valuation, although the company would probably need to grow its earnings at a somewhat faster rate going forward than the sell-side is projecting in order to be a buy at these prices. In addition to Berkshire’s interest, we can see that at the end of Q1 2013 billionaire Stephen Mandel’s Lone Pine Capital had about 2 million shares of DaVita HealthCare Partners Inc in its portfolio (see Mandel’s stock picks). D.E. Shaw, a hedge fund managed by billionaire David Shaw, disclosed ownership of 1.8 million shares (research more stocks D.E. Shaw owned).

The closest peer for DaVita is Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS). Its sales rose by 6% in its last quarterly report compared to the first quarter of 2012, a lower growth rate than what DaVita saw in its core business leaving aside the merger. Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) is actually valued at a small premium to DaVita HealthCare Partners Inc on a forward earnings basis, at a valuation multiple of 16 times expected earnings for 2014. As a result we think that we’d be less interested in doing further research on this company. We can also compare DaVita to specialized health services companies including Mednax Inc. (NYSE:MD), HealthSouth Corp (NYSE:HLS), and Acadia Healthcare Company Inc (NASDAQ:ACHC). The first two of these companies carry forward P/Es of 15, pricing them about in line with DaVita, and each experienced double-digit growth rates on the bottom line in their most recent quarter compared to the same period in the previous year. Markets aren’t actually pricing in much growth at them, either, and so it could be worthwhile to look into whether or not this much earnings growth might be sustainable. Acadia Healthcare Company Inc is expected to substantially improve its business over the next year and a half, but the forward earnings multiple is still above 20 and 13% of the float is held short as many market players are bearish.

We think DaVita HealthCare Partners Inc is a more interesting target than Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS), and we suppose that investors should put at least some weight on Buffett’s interest in the company as well- though the valuation is high enough that we would be cautious in evaluating the business before buying. Mednax Inc. and HealthSouth Corp could be prospects as well.